Literature DB >> 27156615

Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different phenothiazines against Mycobacterium tuberculosis.

Silvan Vesenbeckh1, David Krieger2, Gudrun Bettermann3, Nicolas Schönfeld4, Torsten Thomas Bauer5, Holger Rüssmann6, Harald Mauch7.   

Abstract

Due to an increase of drug resistant TB, alternative drugs that are not currently listed in the WHO guidelines on MDR TB treatment are currently being evaluated. Our group tested 100 susceptible, 20 MDR and 2 XDR Mtb strains against the phenothiazine derivatives thioridazine, trifluoperazine and triflupromazine. MIC testing was performed on Middlebrook 7H10 agar and was defined as the lowest drug concentration that inhibits ≥99% of the bacterial population. We confirm very good in vitro activity of phenothiazines against Mycobacterium tuberculosis. In >77% of all strains MICs of ≤10 μg/ml were found.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Drug development; Efflux pump; Guideline; Public health

Mesh:

Substances:

Year:  2016        PMID: 27156615     DOI: 10.1016/j.tube.2016.02.003

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  3 in total

1.  A Protein Complex from Human Milk Enhances the Activity of Antibiotics and Drugs against Mycobacterium tuberculosis.

Authors:  Virginia Meikle; Ann-Kristin Mossberg; Avishek Mitra; Anders P Hakansson; Michael Niederweis
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 2.  Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action.

Authors:  Leonard Amaral; Miguel Viveiros
Journal:  Antibiotics (Basel)       Date:  2017-01-14

3.  Discovery of Novel Enhancers of Isoniazid Toxicity in Mycobacterium tuberculosis.

Authors:  Fabian Lentz; Norbert Reiling; Ana Martins; Joseph Molnár; Andreas Hilgeroth
Journal:  Molecules       Date:  2018-04-04       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.